In hepatocellular carcinoma, AMPK activation by ferroptosis inducers like erastin, sorafenib, and sulfasalazine inhibits branched chain amino acid transaminase 2 (BCAT2) transcription, modulating glutamate levels and preventing ferroptosis[69]. The gene discussed is BCAT2; the disease is hepatocellular carcinoma.